Literature DB >> 33956350

Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.

Jianfeng Xu1,2, William B Isaacs3, Mufaddal Mamawala3, Zhuqing Shi1, Patricia Landis3, Jacqueline Petkewicz1,2, Jun Wei1, Chi-Hsiung Wang1, W Kyle Resurreccion1, Rong Na1, Yasin Bhanji3, Kristian Novakovic1,2, Patrick C Walsh3, S Lilly Zheng1,2, Brian T Helfand1,2, Christian P Pavlovich3.   

Abstract

BACKGROUND: Prostate cancer (PCa) is characterized by its tendency to be multifocal. However, few studies have investigated the endogenous factors that explain the multifocal disease. The primary objective of the current study is to test whether inherited PCa risk is associated with multifocal tumors in PCa patients.
METHODS: Subjects in this study were PCa patients of European ancestry undergoing active surveillance at Johns Hopkins Hospital (N = 805) and NorthShore University HealthSystem (N = 432). The inherited risk was measured by genetic risk score (GRS), an odds ratio-weighted and population-standardized polygenic risk score based on known risk-associated single nucleotide polymorphisms. PCa multifocality was indirectly measured by the number and laterality of positive tumor cores from a 12-core systematic biopsy.
RESULTS: In the combined cohort, 35.7% and 66.3% of patients had ≥2 tumor cores at the initial diagnostic biopsy and on at least one subsequent surveillance biopsy, respectively. For tumor laterality, 7.8% and 47.8% of patients had bilateral tumor cores at diagnostic and surveillance biopsies, respectively. We found, for the first time, that patients with higher numbers of positive cores at diagnostic and surveillance biopsies, respectively, had significantly higher mean GRS values; p = .01 and p = 5.94E-04. Additionally, patients with bilateral tumors at diagnostic and surveillance biopsies, respectively, had significantly higher mean GRS values than those with unilateral tumors; p = .04 and p = .01. In contrast, no association was found between GRS and maximum core length of tumor or tumor grade at diagnostic/surveillance biopsies (all p > .05). Finally, we observed a modest trend that patients with higher GRS quartiles had a higher risk for tumor upgrading on surveillance biopsies. The trend, however, was not statistically significant (p > .05).
CONCLUSIONS: The associations of GRS with two measurements of PCa multifocality (core numbers and laterality) provide novel and consistent evidence for the link between inherited PCa risk and multifocal tumors.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  active surveillance; genetic risk score; positive cores; prostate cancer

Mesh:

Year:  2021        PMID: 33956350      PMCID: PMC8827243          DOI: 10.1002/pros.24140

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.012


  13 in total

Review 1.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

Review 2.  Multifocal prostate cancer: biologic, prognostic, and therapeutic implications.

Authors:  Matei Andreoiu; Liang Cheng
Journal:  Hum Pathol       Date:  2010-06       Impact factor: 3.466

3.  Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort.

Authors:  Chee L Goh; Edward J Saunders; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Karen Thomas; Elizabeth D Selvadurai; Ruth Woode-Amissah; Tokhir Dadaev; Nadiya Mahmud; Elena Castro; David Olmos; Michelle Guy; Koveela Govindasami; Lynne T O'Brien; Amanda L Hall; Rosemary A Wilkinson; Emma J Sawyer; Ali Amin Al Olama; Douglas F Easton; Zsofia Kote-Jarai; Chris C Parker; Rosalind A Eeles
Journal:  BJU Int       Date:  2013-01-15       Impact factor: 5.588

4.  Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.

Authors:  A Karim Kader; Jielin Sun; Sarah D Isaacs; Kathleen E Wiley; Guifang Yan; Seong-Tae Kim; Helen Fedor; Angelo M DeMarzo; Jonathan I Epstein; Patrick C Walsh; Alan W Partin; Bruce Trock; S Lilly Zheng; Jianfeng Xu; William Isaacs
Journal:  Prostate       Date:  2009-08-01       Impact factor: 4.104

5.  Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.

Authors:  Haitao Chen; Rong Na; Vignesh T Packiam; Carly A Conran; Deke Jiang; Sha Tao; Hongjie Yu; Xiaoling Lin; Wei Meng; S Lilly Zheng; Charles B Brendler; Brian T Helfand; Jianfeng Xu
Journal:  Prostate       Date:  2017-07-02       Impact factor: 4.104

6.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Authors:  Fredrick R Schumacher; Ali Amin Al Olama; Sonja I Berndt; Sara Benlloch; Mahbubl Ahmed; Edward J Saunders; Tokhir Dadaev; Daniel Leongamornlert; Ezequiel Anokian; Clara Cieza-Borrella; Chee Goh; Mark N Brook; Xin Sheng; Laura Fachal; Joe Dennis; Jonathan Tyrer; Kenneth Muir; Artitaya Lophatananon; Victoria L Stevens; Susan M Gapstur; Brian D Carter; Catherine M Tangen; Phyllis J Goodman; Ian M Thompson; Jyotsna Batra; Suzanne Chambers; Leire Moya; Judith Clements; Lisa Horvath; Wayne Tilley; Gail P Risbridger; Henrik Gronberg; Markus Aly; Tobias Nordström; Paul Pharoah; Nora Pashayan; Johanna Schleutker; Teuvo L J Tammela; Csilla Sipeky; Anssi Auvinen; Demetrius Albanes; Stephanie Weinstein; Alicja Wolk; Niclas Håkansson; Catharine M L West; Alison M Dunning; Neil Burnet; Lorelei A Mucci; Edward Giovannucci; Gerald L Andriole; Olivier Cussenot; Géraldine Cancel-Tassin; Stella Koutros; Laura E Beane Freeman; Karina Dalsgaard Sorensen; Torben Falck Orntoft; Michael Borre; Lovise Maehle; Eli Marie Grindedal; David E Neal; Jenny L Donovan; Freddie C Hamdy; Richard M Martin; Ruth C Travis; Tim J Key; Robert J Hamilton; Neil E Fleshner; Antonio Finelli; Sue Ann Ingles; Mariana C Stern; Barry S Rosenstein; Sarah L Kerns; Harry Ostrer; Yong-Jie Lu; Hong-Wei Zhang; Ninghan Feng; Xueying Mao; Xin Guo; Guomin Wang; Zan Sun; Graham G Giles; Melissa C Southey; Robert J MacInnis; Liesel M FitzGerald; Adam S Kibel; Bettina F Drake; Ana Vega; Antonio Gómez-Caamaño; Robert Szulkin; Martin Eklund; Manolis Kogevinas; Javier Llorca; Gemma Castaño-Vinyals; Kathryn L Penney; Meir Stampfer; Jong Y Park; Thomas A Sellers; Hui-Yi Lin; Janet L Stanford; Cezary Cybulski; Dominika Wokolorczyk; Jan Lubinski; Elaine A Ostrander; Milan S Geybels; Børge G Nordestgaard; Sune F Nielsen; Maren Weischer; Rasmus Bisbjerg; Martin Andreas Røder; Peter Iversen; Hermann Brenner; Katarina Cuk; Bernd Holleczek; Christiane Maier; Manuel Luedeke; Thomas Schnoeller; Jeri Kim; Christopher J Logothetis; Esther M John; Manuel R Teixeira; Paula Paulo; Marta Cardoso; Susan L Neuhausen; Linda Steele; Yuan Chun Ding; Kim De Ruyck; Gert De Meerleer; Piet Ost; Azad Razack; Jasmine Lim; Soo-Hwang Teo; Daniel W Lin; Lisa F Newcomb; Davor Lessel; Marija Gamulin; Tomislav Kulis; Radka Kaneva; Nawaid Usmani; Sandeep Singhal; Chavdar Slavov; Vanio Mitev; Matthew Parliament; Frank Claessens; Steven Joniau; Thomas Van den Broeck; Samantha Larkin; Paul A Townsend; Claire Aukim-Hastie; Manuela Gago-Dominguez; Jose Esteban Castelao; Maria Elena Martinez; Monique J Roobol; Guido Jenster; Ron H N van Schaik; Florence Menegaux; Thérèse Truong; Yves Akoli Koudou; Jianfeng Xu; Kay-Tee Khaw; Lisa Cannon-Albright; Hardev Pandha; Agnieszka Michael; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Sara Lindstrom; Constance Turman; Jing Ma; David J Hunter; Elio Riboli; Afshan Siddiq; Federico Canzian; Laurence N Kolonel; Loic Le Marchand; Robert N Hoover; Mitchell J Machiela; Zuxi Cui; Peter Kraft; Christopher I Amos; David V Conti; Douglas F Easton; Fredrik Wiklund; Stephen J Chanock; Brian E Henderson; Zsofia Kote-Jarai; Christopher A Haiman; Rosalind A Eeles
Journal:  Nat Genet       Date:  2018-06-11       Impact factor: 38.330

7.  Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Authors:  H Ballentine Carter; Brian Helfand; Mufaddal Mamawala; Yishuo Wu; Patricia Landis; Hongjie Yu; Kathleen Wiley; Rong Na; Zhuqing Shi; Jacqueline Petkewicz; Sameep Shah; Richard J Fantus; Kristian Novakovic; Charles B Brendler; S Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Eur Urol       Date:  2018-10-08       Impact factor: 20.096

8.  Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Authors:  A Karim Kader; Jielin Sun; Brian H Reck; Paul J Newcombe; Seong-Tae Kim; Fang-Chi Hsu; Ralph B D'Agostino; Sha Tao; Zheng Zhang; Aubrey R Turner; Greg T Platek; Colin F Spraggs; John C Whittaker; Brian R Lane; William B Isaacs; Deborah A Meyers; Eugene R Bleecker; Frank M Torti; Jeffery M Trent; John D McConnell; S Lilly Zheng; Lynn D Condreay; Roger S Rittmaster; Jianfeng Xu
Journal:  Eur Urol       Date:  2012-05-12       Impact factor: 20.096

9.  Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT.

Authors:  Mahbubl Ahmed; Chee Goh; Edward Saunders; Clara Cieza-Borrella; Zsofia Kote-Jarai; Fredrick R Schumacher; Ros Eeles
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-11-27       Impact factor: 5.554

10.  Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Authors:  David V Conti; Burcu F Darst; Lilit C Moss; Edward J Saunders; Xin Sheng; Alisha Chou; Fredrick R Schumacher; Ali Amin Al Olama; Sara Benlloch; Tokhir Dadaev; Mark N Brook; Ali Sahimi; Thomas J Hoffmann; Atushi Takahashi; Koichi Matsuda; Yukihide Momozawa; Masashi Fujita; Kenneth Muir; Artitaya Lophatananon; Peggy Wan; Loic Le Marchand; Lynne R Wilkens; Victoria L Stevens; Susan M Gapstur; Brian D Carter; Johanna Schleutker; Teuvo L J Tammela; Csilla Sipeky; Anssi Auvinen; Graham G Giles; Melissa C Southey; Robert J MacInnis; Cezary Cybulski; Dominika Wokołorczyk; Jan Lubiński; David E Neal; Jenny L Donovan; Freddie C Hamdy; Richard M Martin; Børge G Nordestgaard; Sune F Nielsen; Maren Weischer; Stig E Bojesen; Martin Andreas Røder; Peter Iversen; Jyotsna Batra; Suzanne Chambers; Leire Moya; Lisa Horvath; Judith A Clements; Wayne Tilley; Gail P Risbridger; Henrik Gronberg; Markus Aly; Robert Szulkin; Martin Eklund; Tobias Nordström; Nora Pashayan; Alison M Dunning; Maya Ghoussaini; Ruth C Travis; Tim J Key; Elio Riboli; Jong Y Park; Thomas A Sellers; Hui-Yi Lin; Demetrius Albanes; Stephanie J Weinstein; Lorelei A Mucci; Edward Giovannucci; Sara Lindstrom; Peter Kraft; David J Hunter; Kathryn L Penney; Constance Turman; Catherine M Tangen; Phyllis J Goodman; Ian M Thompson; Robert J Hamilton; Neil E Fleshner; Antonio Finelli; Marie-Élise Parent; Janet L Stanford; Elaine A Ostrander; Milan S Geybels; Stella Koutros; Laura E Beane Freeman; Meir Stampfer; Alicja Wolk; Niclas Håkansson; Gerald L Andriole; Robert N Hoover; Mitchell J Machiela; Karina Dalsgaard Sørensen; Michael Borre; William J Blot; Wei Zheng; Edward D Yeboah; James E Mensah; Yong-Jie Lu; Hong-Wei Zhang; Ninghan Feng; Xueying Mao; Yudong Wu; Shan-Chao Zhao; Zan Sun; Stephen N Thibodeau; Shannon K McDonnell; Daniel J Schaid; Catharine M L West; Neil Burnet; Gill Barnett; Christiane Maier; Thomas Schnoeller; Manuel Luedeke; Adam S Kibel; Bettina F Drake; Olivier Cussenot; Géraldine Cancel-Tassin; Florence Menegaux; Thérèse Truong; Yves Akoli Koudou; Esther M John; Eli Marie Grindedal; Lovise Maehle; Kay-Tee Khaw; Sue A Ingles; Mariana C Stern; Ana Vega; Antonio Gómez-Caamaño; Laura Fachal; Barry S Rosenstein; Sarah L Kerns; Harry Ostrer; Manuel R Teixeira; Paula Paulo; Andreia Brandão; Stephen Watya; Alexander Lubwama; Jeannette T Bensen; Elizabeth T H Fontham; James Mohler; Jack A Taylor; Manolis Kogevinas; Javier Llorca; Gemma Castaño-Vinyals; Lisa Cannon-Albright; Craig C Teerlink; Chad D Huff; Sara S Strom; Luc Multigner; Pascal Blanchet; Laurent Brureau; Radka Kaneva; Chavdar Slavov; Vanio Mitev; Robin J Leach; Brandi Weaver; Hermann Brenner; Katarina Cuk; Bernd Holleczek; Kai-Uwe Saum; Eric A Klein; Ann W Hsing; Rick A Kittles; Adam B Murphy; Christopher J Logothetis; Jeri Kim; Susan L Neuhausen; Linda Steele; Yuan Chun Ding; William B Isaacs; Barbara Nemesure; Anselm J M Hennis; John Carpten; Hardev Pandha; Agnieszka Michael; Kim De Ruyck; Gert De Meerleer; Piet Ost; Jianfeng Xu; Azad Razack; Jasmine Lim; Soo-Hwang Teo; Lisa F Newcomb; Daniel W Lin; Jay H Fowke; Christine Neslund-Dudas; Benjamin A Rybicki; Marija Gamulin; Davor Lessel; Tomislav Kulis; Nawaid Usmani; Sandeep Singhal; Matthew Parliament; Frank Claessens; Steven Joniau; Thomas Van den Broeck; Manuela Gago-Dominguez; Jose Esteban Castelao; Maria Elena Martinez; Samantha Larkin; Paul A Townsend; Claire Aukim-Hastie; William S Bush; Melinda C Aldrich; Dana C Crawford; Shiv Srivastava; Jennifer C Cullen; Gyorgy Petrovics; Graham Casey; Monique J Roobol; Guido Jenster; Ron H N van Schaik; Jennifer J Hu; Maureen Sanderson; Rohit Varma; Roberta McKean-Cowdin; Mina Torres; Nicholas Mancuso; Sonja I Berndt; Stephen K Van Den Eeden; Douglas F Easton; Stephen J Chanock; Michael B Cook; Fredrik Wiklund; Hidewaki Nakagawa; John S Witte; Rosalind A Eeles; Zsofia Kote-Jarai; Christopher A Haiman
Journal:  Nat Genet       Date:  2021-01-04       Impact factor: 38.330

View more
  3 in total

Review 1.  Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.

Authors:  Jianfeng Xu; W Kyle Resurreccion; Zhuqing Shi; Jun Wei; Chi-Hsiung Wang; S Lilly Zheng; Peter J Hulick; Ashley E Ross; Christian P Pavlovich; Brian T Helfand; William B Isaacs
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-28       Impact factor: 5.455

2.  Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.

Authors:  Yu Jiang; Travis J Meyers; Adaeze A Emeka; Lauren Folgosa Cooley; Phillip R Cooper; Nicola Lancki; Irene Helenowski; Linda Kachuri; Daniel W Lin; Janet L Stanford; Lisa F Newcomb; Suzanne Kolb; Antonio Finelli; Neil E Fleshner; Maria Komisarenko; James A Eastham; Behfar Ehdaie; Nicole Benfante; Christopher J Logothetis; Justin R Gregg; Cherie A Perez; Sergio Garza; Jeri Kim; Leonard S Marks; Merdie Delfin; Danielle Barsa; Danny Vesprini; Laurence H Klotz; Andrew Loblaw; Alexandre Mamedov; S Larry Goldenberg; Celestia S Higano; Maria Spillane; Eugenia Wu; H Ballentine Carter; Christian P Pavlovich; Mufaddal Mamawala; Tricia Landis; Peter R Carroll; June M Chan; Matthew R Cooperberg; Janet E Cowan; Todd M Morgan; Javed Siddiqui; Rabia Martin; Eric A Klein; Karen Brittain; Paige Gotwald; Daniel A Barocas; Jeremiah R Dallmer; Jennifer B Gordetsky; Pam Steele; Shilajit D Kundu; Jazmine Stockdale; Monique J Roobol; Lionne D F Venderbos; Martin G Sanda; Rebecca Arnold; Dattatraya Patil; Christopher P Evans; Marc A Dall'Era; Anjali Vij; Anthony J Costello; Ken Chow; Niall M Corcoran; Soroush Rais-Bahrami; Courtney Phares; Douglas S Scherr; Thomas Flynn; R Jeffrey Karnes; Michael Koch; Courtney Rose Dhondt; Joel B Nelson; Dawn McBride; Michael S Cookson; Kelly L Stratton; Stephen Farriester; Erin Hemken; Walter M Stadler; Tuula Pera; Deimante Banionyte; Fernando J Bianco; Isabel H Lopez; Stacy Loeb; Samir S Taneja; Nataliya Byrne; Christopher L Amling; Ann Martinez; Luc Boileau; Franklin D Gaylis; Jacqueline Petkewicz; Nicholas Kirwen; Brian T Helfand; Jianfeng Xu; Denise M Scholtens; William J Catalona; John S Witte
Journal:  HGG Adv       Date:  2021-11-19

3.  Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients.

Authors:  Rocco S Flammia; Benedikt Hoeh; Lukas Hohenhorst; Gabriele Sorce; Francesco Chierigo; Andrea Panunzio; Zhe Tian; Fred Saad; Costantino Leonardo; Alberto Briganti; Alessandro Antonelli; Carlo Terrone; Shahrokh F Shariat; Umberto Anceschi; Markus Graefen; Felix K H Chun; Francesco Montorsi; Michele Gallucci; Pierre I Karakiewicz
Journal:  Int Urol Nephrol       Date:  2022-07-15       Impact factor: 2.266

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.